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Background: Adequate monitoring of cystic fibrosis lung disease is difficult. CF exacerbation offers a unique setting to test the utility of
biomarkers in the assessment of changing airways inflammation. We hypothesised that levels of calprotectin in sputum (and serum) would change
informatively following treatment of an exacerbation.
Methods: 27 patients with CF were recruited at onset of pulmonary exacerbation. Sputum and serum were collected at the start and end of anti-
biotic therapy. Sputum calprotectin, interleukin-8 (IL8), and myeloperoxidase (MPO) were measured, as were serum calprotectin, CRP and
vascular endothelial growth factor (VEGF).
Results: Sputum calprotectin decreased following treatment of an exacerbation (pb0.05), and was superior to other sputum markers. Serum
calprotectin, CRP, and VEGF also decreased significantly (p=0.002, p=0.002, p=0.013 respectively). Serum calprotectin level following
treatment had predictive value for time to next exacerbation (p=0.032).
Conclusions: This study demonstrates the superiority of calprotectin (in sputum and serum) as a biomarker of CF exacerbation over better-
established markers.
© 2010 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.1. Introduction
Cystic fibrosis (CF) lung disease is characterised by chronic
bacterial infection which begins in early childhood, is persistent
throughout life and rapidly evolves to evade host defence
systems [1]. Patients with CF experience recurrent episodes of
increasing pulmonary symptoms, termed exacerbations, which
are accompanied by a decrease in lung function [2]. Viral
infections, including respiratory syncitial virus, may initiate
pulmonary exacerbation [3] but an increase in the density of
colonising organisms [4] or the acquisition of new pathogenic
organisms [5] are also important and as such antibiotic therapy
decreases the bacterial density of respiratory secretions [6,7].
A major difficulty in studying the aetiology and pathophys-
iology of CF exacerbations is the lack of consensus for
diagnostic criteria despite a definite clinical need [8]. Exacer-
bation has been defined in major CF therapeutic trials from⁎ Corresponding author.
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judgement and changes in lung function are most commonly
used to dictate the need for therapy [11]. Irrespective of
definition, CF exacerbation represents an in vivo state of
increasing inflammation in CF lung disease.
Sputum obtained from CF subjects contains a mixture of
proteins which may serve as objective measures of lung
inflammation. Interleukin 8 [IL-8] [11–16], myeloperoxidase
[MPO] [17–20], matrix metaloproteinase 9 [MMP-9] [21] and
neutrophil elastase [NE] [13,16,22] have all been advocated and
studied. NE and IL-8 correlate inversely to lung function,
suggesting a relationship of sputum markers to disease severity
[23]. We have recently described calprotectin (also known as
calgranulin A/B, S100A8/A9, MRP8/14, CF antigen) in BALF
[24] and sputum [25] as a biomarker of CF lung disease.
Calprotectin was first described in the serum of CF patients in
1975[26], and later became known as CF antigen[27]. In spite
of being present in CF lung secretions in high concentrations,
the function of calprotectin in the CF lung and its mechanism of
action have yet to be explored. Calprotectin is highly abundant
in neutrophils, has pro-inflammatory properties via activation ofd by Elsevier B.V. All rights reserved.
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inflammation in non-CF models of lung infection[29].
Sputum protein profiles [17] and cytokine levels such as
IL-8 have been demonstrated to change following treatment of
CF exacerbations with antibiotic therapy [6,7], although this is
not a consistent finding in all studies[30]. Altering the level of
bacterial burden in the lung with antibiotic therapy may alter
the inflammatory milieu. Thus we may use this model to study
the clinical significance of new markers of CF lung disease.
Other groups have used exacerbation in CF to demonstrate the
presence of novel biomarkers, for example prostaglandin E2
and cys-leukotrienes, mediators of oxidative stress, were
elevated in CF exacerbation compared to stable CF [31] as
was HMGB1[32], although these studies did not utilise serial
samples in the same patients. Serial monitoring has been used
for serum vascular endothelial growth factor, which appears to
be a marker of inflammatory change following treatment of
CF exacerbation with antibiotic therapy [33].
On the basis of our previous work with calprotectin [24,25]
we hypothesised that calprotectin (sputum and serum) would
change informatively following treatment of CF exacerbation.
We wished to compare its utility to previously assessed
biomarkers, sputum IL-8 and serum CRP and VEGF.Table 1
Patient Demographics, colonising organism and antibiotic treatment.
Patient M/F Genotype Age FEV1% Pred Start
1 f ΔF508/3659ΔC 20 67
2 f ΔF508/ΔF508 30 42
3 f ΔF508/ΔF508 20 13
4 f ΔF508/ΔF508 18 55
5 f ΔF508/G551D 18 23
6 m ΔF508/Unk 46 36
7 f ΔF508/ΔF508 21 56
8 m ΔF508/ΔF508 18 58
9 f ΔF508/G551D 31 31
10 m ΔF508/ΔF508 18 33
11 f ΔF508/ΔF508 20 60
12 m ΔF508/Unk 32 75
13 f ΔF508/P67L 27 45
14 f ΔF508/G542X 23 50
15 f ΔF508/ΔF508 22 66
16 f ΔF508/Unk 17 38
17 m ΔF508/G542X 22 56
18 m ΔF508/G551D 41 24
19 m ΔF508/ΔF508 24 41
20 m ΔF508/ΔF508 37 21
21 f ΔF508/ΔF508 22 45
22 f ΔF508/ΔF508 18 15
23 m ΔF508/G551D 20 28
24 f ΔF508/ΔF508 26 61
25 m ΔF508/ΔF508 17 23
26 m ΔF508/ΔF508 17 33
27 m ΔF508/3849+10 kb C→T 22 34
Unk = unknown.
Colonising organisms relate to most recent sputum culture prior to exacerbation
cenocepacia, BMV=Burkholderia multivorans, SA=Staph aureus, SM=Stenotropho
Treatment for exacerbation was with intravenous antibiotics apart from sub
CIP=ciprofloxacin, CFZ=ceftazidime, CO=colomycin, COAMOX=coamoxiclav,
pipericillin, TO=Tobramycin.2. Methods
The Lothian Hospitals Ethics Committee granted approval
for this study. Patients were recruited at the time of a pulmonary
exacerbation requiring antibiotics, as determined by the
patient's physician on the basis of increased breathlessness,
increased sputum production and a decrease from baseline
FEV1. Sputum and serum were collected for the assessment of
biomarkers within 24 hrs of commencing treatment with
antibiotics and again at cessation. This ranged from one to
three weeks of therapy. FEV1 was recorded at these time points.
Sputum was processed within 2 hours of collection as
described previously [34]. In brief, sputum plugs were
harvested and processed with 4x weight/volume 0.1% dithio-
threitol (DTT) after which 4x weight/volume PBS was added.
Samples were filtered through 48 μm mesh and centrifuged at
1200 rpm to remove the cells. Supernatant was stored at -80 °C
until further analysis. The cell pellet was re-suspended in PBS,
cytospins prepared and stained with May-Grunwald-Giemsa for
differential cell counting. All counts were expressed as
percentage of the population counted. All samples utilised in
the study contained b40% squamous cells ensuring samples
were from the lower airway.FEV1% Pred End Colonising Organism Treatment For Exacerbation
66 BC, SM, HI, SA TO, CFZ
49 PA, SA TO, CFZ
13 PA CO, MER
60 PA TO, CFZ
39 BC UnK
38 PA, SM TO, CFZ
59 PA, SA TO, MER
59 MRSA, SA TO, CFZ
49 PA CFZ, CIP
43 SA, SM TAZ, MIN
73 PA, Asp TO, MER
88 PA CIP, AZI
49 SA, BMV TO, CFZ
82 SA, HI TO, CFZ
75 PA, SA CO, CFZ
44 SA FL, COAMOX
52 PA TO, MER, AZ
31 SM, PA, SA. Asp TO, MER
49 SA, PA, SM TO, CFZ
27 BC, PA TO, MER
52 PA TO, MER
15 PA, SA AZ, MER
28 PA TO, CFZ
64 PA, SM, Asp TO, CFZ
28 PA CO, MER
45 PA, SA TO, CFZ
49 PA TO, CFZ
recorded for each patient. PA=Pseudomonas aeruginosa, BC=Burkholderia
monas maltophillia, HI=Haemophilus influenzae, Asp=Aspergillus fumigatus.
ject 12 who received oral treatment. AZ=aztreonam, AZI=azithromycin,
FL=flucloxacillin, MER=meropenem, MIN=minocycline, TAZ=tazobactam/
Table 2
Measurements taken at the start and end of exacerbation treatment.
Measurement Start of Exacerbation End of Treatment
FEV1% predicted 41.8(3.2) 49.1(3.6) ⁎⁎
Sputum Calprotectin μg/ml 619.4 (484.1- 971.9) 274.4 (184.0-570.9) ⁎
Sputum IL8 ng/ml 30.8(18.8-53.4) 20.6(10.3-60.5)
Sputum MPO μg/ml 41.3(18.6-49.8) 24.4(8.8-45.5)
Sputum Neutrophil % 98.8(97.2-99.6) 97.5(95.6-98.7) ⁎
WCC 109 11.8 (0.9) 9.0(1.5) ⁎⁎
CRP mg/ml 35.6(8.6-75.2) 9.9(3.0-23.5) ⁎⁎
Serum Calprotectin μg/ml 21.5 (13.3-55.5) 9.3 (6.5-18.2) ⁎⁎
Serum VEGF 385 (226- 582) 236 (143- 412) ⁎
Data are displayed as median (IQR) or mean (SEM) depending on normality of
distribution. Paired analysis was performed to investigate which markers
changed most significantly with treatment, for exact p values please see text.
⁎ pb0.05.
⁎⁎ pb0.01.
Fig. 1. Panel A. Sputum calprotectin decreases over the course of an
exacerbation following treatment with antibiotics; p=0.013. Individual data
are shown for 27 subjects. Panel B. Serum calprotectin decreases over the course
of an exacerbation following treatment with antibiotics; p=0.002. Individual
data are shown for 25 subjects.
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activator (Monovette serum collection tubes, Sarstedt AG and
Co, Germany). The tube was then mixed by inverting 5 times.
Blood was left to clot at room temperature for 45 minutes.
Tubes were centrifuged at 1800×g for 15 minutes at room
temperature. Separated serum was removed into cryovials
(Nunc, Thermo Fisher Scientific, Denmark) as above and stored
at -80 °C until further analysis. A separate EDTA blood sample
was taken for routine haematology (white cell count).
Calprotectin was measured in sputum and serum by a double
antibody sandwich ELISA, using monoclonal and polyclonal
antibodies against human calprotectin complex (gift of Erling
Sundrehagen, Norway). Interleukin 8 (Biosource, UK); myeloper-
oxidase (Assay Designs, Michigan, USA); CRP; and VEGF
(Quantikine, R and D Systems, Oxford, UK); were measured using
commercial kits according to the manufacturers’ instructions. All
standard curves and dilutions for sputum ELISAs were performed
in the presence of 0.05% DTT to ensure accurate measurement of
mediators in sputum as samples had been processed with DTT.
2.1. Prediction of future exacerbations
To investigate whether serum calprotectin at the end of
exacerbation could predict patient outcome the clinical case notes
were reviewed 1 year following completion of the study and the
time to next exacerbation calculated in days. A cut off 9.1 μg/ml
(median value in stable non-exacerbating CF subjects) was
employed and this divided the group into 13 (b9.1 μg/ml) and 12
(N9.1 μg/ml) patients. The same analysis was performed for CRP
using a cut off level of 10 mg/ml (upper limit of normal).
2.2. Statistical analyses
Data analyses were performed with GraphPad Prism
software (GraphPad, La Jolla, Ca, USA). Normally distributed
data were analysed by paired t test and non-normally distributed
data by Wilcoxon sign rank test. Kaplan Meier curves were
compared by log rank (Mantel Cox) testing.
3. Results
Twenty-seven patients completed the study (demographics
in Table 1). FEV1 improved over the course of an exacerbation,
increasing from 41.8 (SEM 3.2) to 49.1 (3.6)% predicted
(p=0.001). Whole blood white cell count decreased from 11.8
(SEM 0.9) to 9.0 (1.5) (p=0.004) and sputum neutrophils from
98.8% to 97.5% (p=0.04), see Table 2.
3.1. Sputum results
Due to limitations in sputum sample size not all patients could
be assessed for all biomarkers (priority was given to sputum
calprotectin which was measured in all 27 paired samples). There
was a significant reduction in the level of calprotectin from
median 619.4 (IQ range; 484.1- 971.9)μg/ml to 274.4 (184.0-
570.9)μg/ml (p=0.013; Fig. 1). Sputum IL8 and MPO were
measured in 26 paired samples (Table 2). Sputum IL8 showed atrend to decrease following treatment, from median 30.8 (18.8-
53.5)ng/ml to 20.6 (10.3-60.6)ng/ml (p=0.11). Sputum MPO
showed a trend to decrease following treatment, frommedian 41.3
(18.6-49.8)μg/ml to 24.4 (8.8-45.5)μg/ml (p=0.07).
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Serum was available in 25 patients from 27 recruited as two
declined venepuncture. Serum calprotectin decreased from
median 21.5 (13.3-55.5)μg/ml to 9.3 (6.5-18.2) (p=0.002; Fig. 1).
Serum CRP decreased from median 35.6 (8.7-92.0)mg/ml. to 9.9
(3.0-23.5) (n=22 paired samples [3 single sampleswere above the
limit of detection of the assay: 300 mg/ml]; p=0.002; Table 2).
SerumVEGFdecreased frommedian 385 (226- 582)pg/ml to 236
(143- 412) (p=0.013; Fig. 2).
3.3. Significant correlations
Serum calprotectin was negatively correlated with FEV1
(Spearman r -0.49 [pb0.012] pre-treatment vs. -0.38 [p=0.056]
post-treatment), giving an overall Spearman r of -0.48
(p=0.0004) for calprotectin and FEV1 before and after
exacerbation treatment. Serum CRP correlated less well with
lung function (Spearman r -0.32 [p=0.12] pre-treatment vs. -0.26
[p=0.21] post-treatment), giving an overall Spearman r of -0.36
(p=0.011) for CRP and FEV1 before and after exacerbation
treatment. Sputum calprotectin did not significantly correlate with
lung function.
3.4. Predictive values of serum markers
The median time to exacerbation in patients with calprotectin
N9.1 μg/ml was 70 days compared to 112 days in the b9.1 μg/ml
group (p=0.032; Fig. 4). Three patients in the N9.1 μg/ml group
died within 18 months of their final study visit. CRP failed to
show a difference in the median time to next exacerbation 81
(b10 mg/ml) vs. 84 (N10 mg/ml) days (p=0.12; Fig. 3).
4. Discussion
We have demonstrated that treatment of an exacerbation with
antibiotic therapy in CF results in decreasing levels of sputum
and serum calprotectin. Serum CRP and VEGF also decreased.
We have also demonstrated a predictive value of serumFig. 2. Serum VEGF decreases over the course of an exacerbation following
treatment with antibiotics; p=0.013. Individual data are shown for 23 subjects.calprotectin at the end of exacerbation treatment for time to
next exacerbation.
Sputum calprotectin decreased following treatment of a CF
exacerbation. We have previously demonstrated high levels of
calgranulins A and B (the constituent subunits of calprotectin),
by mass spectrometry, in CF sputum and BALF[24,25].
Calprotectin may be secreted from stimulated neutrophils
[35], or released at cell death [36] and as such is an appropriate
marker for inflammation in the CF airway. Faecal calprotectin
has been recognised as a marker of organic bowel disease [37]
and can differentiate inflammatory bowel disease, which is
neutrophil predominant, from irritable bowel syndrome [38].
Calprotectin may play an important mechanistic role in the CF
airway and has been previously implicated in early lung disease
in animal models [39]. Furthermore functional knock out of
calprotectin in a murine model of pneumonia leads to decreases
in inflammatory cell recruitment suggesting an integral role in
inflammatory cell recruitment [29]. Thus the change in sputum
calprotectin following antibiotic therapy implies a direct
association of calprotectin with a changing state of airways
inflammation. The exploration of a possible role of calprotectin
as a pro-inflammatory molecule in the lung requires further
work.Fig. 3. Panel A. Subjects with serum calprotectin of 9.1 mg/ml at the end of
exacerbation treatment have longer time to next exacerbation with median time
to exacerbation 112 days vs. 70 days (p=0.032). Panel B. Serum CRP of
b10 mg/ml did not differentiate time to next exacerbation with median time to
exacerbation of 81 vs. 83.5 days (p=0.125).
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sputum IL-8 or MPO following antibiotic therapy, although
there were trends to reduction. Decreases in sputum IL-
8 following IV antibiotic treatment have been described [6,7],
with similar findings reported following nebulised antibiotic
therapy [40]. Our study was performed using spontaneously
expectorated sputum in line with both Colombo et al [7] and
Husson et al [40], but in contrast to Ordonez et al [6], who
induced sputum. We do not believe our study was underpow-
ered to demonstrate a change in sputum IL-8 (a secondary
outcome), as other groups have demonstrated changes in
sputum IL-8 with similar sized patient cohorts [7,40]. The
largest study demonstrating changes in sputum IL-8 following
antibiotic therapy was performed by Ordonez et al, utilising 42
paired samples and demonstrating a modest decrease in sputum
IL-8 (0.5+ /- 1.3 log10 pg/ml) [6]. Therefore even if our study
was underpowered to detect changes in IL-8 (which we feel
unlikely) we have clearly demonstrated the superiority of
sputum calprotectin measurement in this population. One
possible explanation for our failure to demonstrate a decrease
in IL-8, is that our study utilised an adult population with more
severe disease compared to Ordonez et al who excluded patients
with an FEV1 of less than 40% [6]. Indeed Downey et al
demonstrated no serial change in sputum IL-8 in CF adults
following exacerbation treatment, further underlining the
possibility that sputum IL-8 is not as powerful a marker in the
older patient group[30]. This suggests that IL-8 is a less reliable
marker in patients with more advanced lung disease and is
consistent with the finding that sputum IL-8 is less well
correlated to lung function that other sputum markers such as
free elastase [23].
Sputum MPO has been less well studied. As a neutrophil
protein we might have expected a change in sputum concentra-
tions following treatment of an exacerbation, and it has been
described at high levels in CF sputum compared to control
populations [17–20]. The failure to demonstrate a significant
change in MPO may be explained by many of the points
pertinent to IL-8. And our findings are consistent with a study of
oral macrolide antibiotics in CF patients infected with P.
aeruginosa, which demonstrated no change in sputum MPO
following treatment [41]. Also, MPO is a primary granule
protein in the neutrophil and as such we could postulate its
release from neutrophils may be more tightly controlled than
that of calprotectin, a cytoplasmic protein.
Serum calprotectin decreased over the course of an
exacerbation. This finding was of higher statistical significance
than calprotectin in sputum suggesting less variability in serum
sampling than sputum. Calgranulin A (sub-unit of calprotectin)
has previously been described in the serum of homozygotes and
heterozygotes with CF mutations as CF antigen [26]. The serum
levels of calprotectin are approximately 4 fold less than those
observed in sputum, suggesting that the high concentrations of
calprotectin observed in sputum are likely to arise locally in the
airways from neutrophils, in particular from necrotic neutro-
phils, which are more prevalent in the sputum of CF patients
with gram negative infection [42]. Changing levels of
calprotectin in serum may reflect increased neutrophil recruit-ment from the bone marrow or leak of calprotectin from the
lungs into the systemic circulation due to a breakdown in
epithelial barrier integrity although further work is required to
investigate this.
Serum CRP and VEGF also decreased significantly. This
may have been anticipated as CRP is an acute phase protein
previously recognised to change in CF exacerbations [7]. Serum
VEGF has also been demonstrated to decrease with treatment of
a CF exacerbation, with the main source being postulated as
hypoxic lung tissue [33]. In our study both serum CRP and
VEGF fell, consistent with previous studies. Serum CRP was
demonstrated to show a similar serial change to serum
calprotectin following exacerbation treatment but was less
well correlated to lung function suggesting a more significant
relationship of serum calprotectin to the airway than CRP.
However this study does suggest a role for the measurement of
CRP in the clinical management of CF exacerbations.
Serum calprotectin concentrations of b9.1 μg/ml at the end
of an exacerbation predicted a delayed time to next exacerba-
tion, with the median time being 112 days vs. 70 days for
patients with calprotectin N9.1 μg/ml. Indeed three patients in
low serum calprotectin group had not exacerbated by 1 year,
whereas 3 patients in the high group had died by the time of
follow up. CRP was less good in this regard, with no difference
in median time to next exacerbation between those patients with
normal and those with raised CRP values at the end of
exacerbation. Further studies are now required to assess and
validate serum calprotectin as a predictor of outcome in CF, but
the current data raise the possibility that calprotectin levels may
inform whether treatment needs to be prolonged.
We conclude that sputum and serum calprotectin decrease
significantly with treatment of an exacerbation and are superior
to sputum IL8 and serum CRP and VEGF, all of which have
been advocated hitherto, as indicators of response. The
additional value of a serum biomarker is recognised because
of the greater ease of sample acquisition and processing. Further
investigation is required to assess the potential clinical impact of
these novel observations.
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